Posted by Carter McIntosh.
Valeant is a very large pharmaceutical company that focused on creating a “drug giant that was focused on distribution.” Valeant “was” one of the hottest stocks on Wall Street; this stock was booming; the stock soared all the way to $260 in just months. Wall Street analysts and Hedge Funds loved Valeant and everyone wanted to own it. Valeant has been in the news lately, and it is not good news but rather some very bad news. Allegations now follow Valeant and whether or not they have true success or that there true success can be attributed to “price gouging: a secret network of specialty pharmacies; and fraud.” With these allegations surfacing, Valeant stock has “plummeted 60% in the last three months.”
Valeant has been under scrutiny for a while now, dating all the way back to August 14th, 2015. In August, Valeant was being scrutinized because they raised the price of their drugs. On October 5th, 2015, a study by a Deutsche Bank analyst finds that it is not just two drugs that they raised the prices. The report concludes that Valeant has jacked up prices on 54 other meds this year alone, by an average of 66%.” In response to this issue, Valeant CEO Pearson said during an earnings call on October 19th, 2015, that “Valeant will ease up on its strategy of buying up drugs that are mispriced and hiking the prices.”
On October 20th, 2015 “A report by Citron Research, run by activist short seller Andrew Left reveals more information about Philidor and it’s network of phantom captive pharmacies.” Left accused Valeant of committing accounting fraud; furthermore, Left compared “Valeant to companies like Enron.” Two days later on October 22nd, 2015, Valeant “called Left’s reports erroneous. The company says it hasn’t used Philidor to book false sales. It says Philidor is a separate company, but that Philidor’s financial statements are included in Valeant’s financial statements.” With this allegation surfacing Valeant shares have plummeted 30% in just three days.
As more and more information surfaced about Valeant’s relationship with Philidor, on October 30th, 2015, “Valeant says it is cutting ties to Philidor, and that the pharmacy will shut down immediately. Allegations have emerged that Philidor may have changed prescriptions to push Valeant’s high-priced drugs on patients, rather than the generics.” Bill Ackman, the largest shareholder in Valeant held a “four – hour conference call to defend Valeant,” as he believes in Valeant’s business strategy and that the company would not commit accounting fraud and price gouging. Unfortunately, this course of action did not help Valiant. In fact, after the Bill Ackman conference call, Valeant shares fell another 10%.
Carter is a finance major at the Stillman School of Business, Seton Hall University, Class of 2018.